Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
Rhea-AI Summary
Minerva Neurosciences (Nasdaq: NERV) announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will present at The Citizens Life Sciences Conference in Miami on March 10-11, 2026.
The company will deliver a company presentation on Tuesday, March 10 at 9:35 AM ET; a live webcast and a replay available for ninety days will be provided, according to the company.
Positive
- None.
Negative
- None.
News Market Reaction – NERV
In the Mar 4 session, NERV declined 0.44%, reflecting a mild negative market reaction. Argus tracked a trough of -20.7% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 4.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-01-26 | KOL event announcement | Positive | +2.5% | Announced virtual KOL event on roluperidone and planned 2026 Phase 3 trial. |
| 2025-11-19 | Board and financing update | Positive | +0.0% | Appointed new director and highlighted private placement up to $200 million. |
| 2025-11-05 | Q3 2025 results | Positive | +4.1% | Reported Q3 2025 results and detailed $80M upfront plus additional warrant funding. |
| 2025-10-21 | Phase 3 financing | Positive | +141.0% | Announced financing of up to $200M to fund Phase 3, NDA resubmission, launch prep. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news on financing, clinical planning, and events has generally aligned with positive or flat next-day price reactions, including a very strong move on the major October 2025 financing update.
Over the past several months, Minerva has focused on financing and clinical execution for roluperidone. In October 2025, it announced financing of up to $200 million tied to a confirmatory Phase 3 trial and NDA resubmission, which saw a 140.98% next-day move. Subsequent Q3 2025 results and an October private placement update were associated with a $80 million upfront raise and modestly positive reaction. A January 2026 KOL event announcement also drew a positive response. Today’s conference participation fits within this cadence of ongoing investor and scientific outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL.
| The Citizens Life Sciences Conference | |
| Format: | Company presentation |
| Day/Time: | Tuesday, March 10 at 9:35 AM ET |
| Webcast: | https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/SKrutqyvQVtnaKJDseE6uU |
If you are interested in meeting with the Minerva team during the conference, please reach out to your Citizens Bank representative.
A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Contacts:
Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
FAhlholm@minervaneurosciences.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
